Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesEmergent Biosolutions Inc

Emergent Biosolutions Inc

Healthcare Drug Manufacturers - Specialty & Generic
PortfolioPortfolio WatchlistWatchlist
Company price
6.265 USD -0.17 ( 2.72%)
Last update at 2026-11-03T20:54:00Z
VOLUME
2751201
Market Cap
326.10M

Momentum Score

…

Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States, Canada, and internationally. It operates through Commercial Products, MCM Products, and All Other Revenues segments. The company offers ACAM2000, a smallpox and mpox vaccine; Anthrax Immune Globulin Intravenous (ANTHRASIL), a polyclonal antibody therapeutic for the treatment of inhalational anthrax; Botulism Antitoxin Heptavalent (BAT), an equine plasma antitoxin for the treatment of symptomatic botulism; BioThrax, an anthrax vaccine; CYFENDUS, a vaccine for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; Ebanga, a monoclonal antibody for the treatment of infection caused by Orthoebolavirus zairense; Raxibacumab injection, a monoclonal antibody therapeutic for the treatment and prophylaxis of inhalational anthrax due to Bacillus anthracis; TEMBEXA, an oral antiviral for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; and CNJ-016, a polyclonal antibody therapeutic to address complications from smallpox vaccination. It also provides NARCAN and KLOXXADO nasal sprays for the emergency treatment of known or suspected opioid overdose. In addition, the company offers contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, analytical development, and suite reservation services. Emergent BioSolutions Inc. was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
5.51
Low
7.22
High
52 Week Price Range
4.36
Low
14.06
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Emergent Biosolutions develops, manufactures and supplies vaccines, therapeutics and related manufacturing services for public health threats, with a focus on anthrax and other biodefense countermeasures. Long-term growth may be supported by government stockpiling programs, pandemic preparedness funding and expansion of its contract-manufacturing services and product pipeline. Investors may find the company attractive for its specialized portfolio and established relationships with public health agencies.

Risk Score
Medium

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
6.44
Dividend Yield
-
Revenue TTM
770.20M
Revenue Per Share
14.76
Gross Profit TTM
388.50M
Debt / Equity
1.09
ROE
-40.29%
Net Debt
366.70M
ROCE
9.29%
Diluted EPS TTM
-3.40

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax 82.80M -142.90M -731.20M -221.70M 314.40M
Net income 52.60M -190.60M -760.50M -223.80M 230.90M
Selling general administrative 186.10M 308.00M 372.90M 340.30M 347.50M
Gross profit 350.60M 375.40M 360.00M 427.20M 1035.20M
Reconciled depreciation 95.80M 108.80M 131.20M 143.30M 123.80M
Ebit 110.20M -52.20M -168.10M -166.00M 352.60M
Ebitda 208.50M 53.40M -47.00M -34.40M 514.40M
Depreciation and amortization 98.30M 105.60M 121.10M 131.60M 161.80M
Non operating income net other - - - -11.70M -3.70M
Operating income 110.20M -108.70M -726.40M -166.00M 352.60M
Other operating expenses 632.70M 1152.30M 1775.70M 1286.90M 1398.40M
Interest expense 59.30M 71.00M 87.90M 37.30M 34.50M
Tax provision 30.20M 47.70M 49.40M 2.10M 83.50M
Interest income 59.30M 71.00M 87.90M 37.30M 34.50M
Net interest income -59.30M -71.00M -79.00M -37.30M -34.50M
Income tax expense 30.20M 47.70M 29.30M 2.10M 83.50M
Total revenue 742.90M 1043.60M 1049.30M 1120.90M 1792.70M
Total operating expenses 240.40M 484.10M 1086.40M 593.20M 640.90M
Cost of revenue 392.30M 668.20M 689.30M 693.70M 757.50M
Total other income expense net -27.40M -34.20M -4.80M -55.70M -38.20M
Net income from continuing ops 52.60M -190.60M -790.20M -223.80M 230.90M
Net income applicable to common shares 52.60M -190.60M -760.50M -223.80M 230.90M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 1318.60M 1389.70M 3166.60M 3166.60M 2959.00M
Intangible assets 436.50M 501.50M 728.80M 728.80M 604.60M
Other current assets 29.50M 33.00M 57.90M 57.90M 70.50M
Total liab 796.00M 906.90M 1783.60M 1783.60M 1340.00M
Total stockholder equity 522.60M 482.80M 1383.00M 1383.00M 1619.00M
Deferred long term liab - - - 71.80M 94.90M
Other current liab 76.60M 98.80M 142.70M 169.10M 72.90M
Common stock 0.10M 0.10M 0.10M 0.10M 0.10M
Capital stock 0.10M 0.10M 0.10M 0.10M 0.10M
Retained earnings -159.80M -212.40M 734.00M 734.00M 957.80M
Other liab - - - 90.40M 156.80M
Good will - - 218.20M 218.20M 224.90M
Other assets 3.60M 7.20M - 191.30M 57.30M
Cash 205.40M 99.50M 642.60M 642.60M 576.10M
Cash and equivalents 205.40M 99.50M - 642.60M 576.10M
Total current liabilities 132.20M 162.40M 1229.90M 1229.90M 373.80M
Current deferred revenue - - 26.40M - 140.40M
Net debt 366.70M 576.60M 763.20M 763.20M 264.90M
Short term debt 0.00M 2.70M 957.30M 957.30M 31.60M
Short long term debt - - 413.70M 957.30M 31.60M
Short long term debt total 572.10M 676.10M 1405.80M 1405.80M 841.00M
Other stockholder equity 689.80M 700.30M 645.80M 645.80M 677.20M
Property plant equipment 216.00M 282.30M - 817.60M 800.10M
Total current assets 662.50M 598.70M 1210.70M 1210.70M 1272.10M
Net tangible assets - - - 1383.00M 1619.00M
Short term investments - - 8.50M - -
Net receivables 84.20M 154.50M 158.40M 158.40M 274.70M
Long term debt 572.10M 663.70M 446.50M 448.50M 809.40M
Inventory 343.40M 311.70M 351.80M 351.80M 350.80M
Accounts payable 55.60M 60.90M 103.50M 103.50M 128.90M
Accumulated other comprehensive income -7.50M -5.20M 3.10M 3.10M -16.10M
Common stock total equity - - - 0.10M 0.10M
Retained earnings total equity - - - 734.00M 957.80M
Treasury stock - - - -227.70M -152.20M
Non currrent assets other 14.20M 18.90M 191.30M 191.30M 57.30M
Non current assets total 656.10M 791.00M 1955.90M 1955.90M 1686.90M
Long term debt total 572.10M 663.70M - 448.50M 809.40M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - 125.20M 178.30M -381.30M -225.00M
Change to liabilities - - - -52.00M -7.70M
Total cashflows from investing activities 69.40M 125.20M - -381.30M -225.00M
Net borrowings -108.70M -198.40M - 564.20M -35.90M
Total cash from financing activities -136.60M -190.00M 481.20M 481.20M -141.00M
Change to operating activities - - - -86.50M -29.90M
Net income 52.60M -190.60M -223.80M -223.80M 230.90M
Change in cash 103.50M -6.10M 66.30M 66.30M -45.20M
Begin period cash flow 105.60M 111.70M 576.30M 576.30M 621.50M
End period cash flow 209.10M 105.60M 642.60M 642.60M 576.30M
Total cash from operating activities 170.60M 58.70M -34.10M -34.10M 321.10M
Issuance of capital stock 0.00M 9.30M 8.40M 0.00M 0.00M
Depreciation 95.80M 108.80M 143.30M 143.30M 123.80M
Other cashflows from investing activities 83.20M 148.10M - -21.80M -21.80M
Dividends paid - - 5.00M - 15.90M
Change to inventory -30.30M -24.50M -51.90M -51.90M -44.00M
Change to account receivables 25.50M -24.40M 114.70M 114.70M -48.20M
Sale purchase of stock -24.90M 24.20M -82.10M -82.10M -106.00M
Other cashflows from financing activities -1.40M -0.90M 597.10M 597.10M -35.00M
Change to netincome - - - 41.80M 118.70M
Capital expenditures 13.80M 22.90M 115.80M 115.80M 225.00M
Change receivables - - - 114.70M -48.20M
Cash flows other operating - - - -10.30M -56.50M
Cash and cash equivalents changes - - - 65.80M -44.90M
Change in working capital -22.40M 88.70M 0.50M 0.50M -94.70M
Stock based compensation 16.20M 18.00M 45.10M 45.10M 42.40M
Other non cash items 32.40M 39.30M 19.80M 19.80M -28.20M
Free cash flow 156.80M 35.80M -149.90M -149.90M 96.10M

Peer Comparison*

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
EBS
Emergent Biosolutions Inc		 -0.17
2.72%		 6.26 - 21.98 0.42 0.96 1.04 5.24
MKKGY
Merck KGaA ADR		 -0.50
1.48%		 33.21 21.25 14.93 3.10 2.14 3.60 12.98
MKGAF
MERCK Kommanditgesellschaft auf Aktien		 -1.26
0.75%		 167.45 24.86 15.11 3.13 1.98 3.08 18.89
TAK
Takeda Pharmaceutical Co Ltd ADR		 -
-%		 20.75 - 10.96 0.01 1.20 2.94 23.11
TKPHF
Takeda Pharmaceutical Co. Ltd.		 -0.91
2.17%		 41.09 - 10.66 0.01 1.16 2.94 23.11

Profile*

Emergent Biosolutions Inc

Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States, Canada, and internationally. It operates through Commercial Products, MCM Products, and All Other Revenues segments. The company offers ACAM2000, a smallpox and mpox vaccine; Anthrax Immune Globulin Intravenous (ANTHRASIL), a polyclonal antibody therapeutic for the treatment of inhalational anthrax; Botulism Antitoxin Heptavalent (BAT), an equine plasma antitoxin for the treatment of symptomatic botulism; BioThrax, an anthrax vaccine; CYFENDUS, a vaccine for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; Ebanga, a monoclonal antibody for the treatment of infection caused by Orthoebolavirus zairense; Raxibacumab injection, a monoclonal antibody therapeutic for the treatment and prophylaxis of inhalational anthrax due to Bacillus anthracis; TEMBEXA, an oral antiviral for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; and CNJ-016, a polyclonal antibody therapeutic to address complications from smallpox vaccination. It also provides NARCAN and KLOXXADO nasal sprays for the emergency treatment of known or suspected opioid overdose. In addition, the company offers contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, analytical development, and suite reservation services. Emergent BioSolutions Inc. was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.

300 Professional Drive, Gaithersburg, MD, United States, 20879

240 631 3200

https://www.emergentbiosolutions.com

900

Name Title Year Born
Mr. Robert G. Kramer Sr. CEO, Pres & Exec. Director 1957
Mr. Richard S. Lindahl Exec. VP, CFO & Treasurer 1964
Mr. Adam R. Havey Exec. VP & COO 1971
Mr. Atul Saran Exec. VP & Chief Strategy and Devel. Officer 1973
Mr. Robert G. Burrows VP of Investor Relations NA
Ms. Jennifer L. Fox Exec. VP of External Affairs, Gen. Counsel & Corp. Sec. NA
Ms. Coleen Glessner Exec. VP of Global Quality and Ethics & Compliance NA
Ms. Lynn Kieffer VP of Corp. Communications NA
Ms. Katherine Strei Exec. VP of HR & Chief HR Officer 1962
Mr. Richard S. Lindahl M.B.A. Executive VP, CFO & Treasurer 1964

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

VNP
CAD 32.54
+24.44%
HUT
CAD 88.32
+14.81%
KEEL
CAD 3.05
+14.66%
MTY
CAD 36.63
+13.58%
CNL
CAD 15.98
+11.90%
MOON
CAD 4.72
-12.34%
EU
CAD 0.96
-8.57%
URE
CAD 1.02
-8.48%
AP-UN
CAD 3.71
-8.17%
HG
CAD 3.77
-8.05%

Equity Sectors*

  • Basic Materials

    -1.14%

  • Communication Services

    +0.65%

  • Consumer Cyclical

    +0.09%

  • Consumer Defensive

    -0.57%

  • Energy

    -0.15%

  • Financial Services

    +0.08%

  • Healthcare

    +2.18%

  • Industrials

    +2.04%

  • Real Estate

    -0.25%

  • Technology

    +1.02%

  • Utilities

    +0.66%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…